Glass Health

Bottom line

Glass Health is a clinical reasoning assistant that generates differential diagnoses, literature-grounded assessment and plan recommendations, and ambient documentation from a single workflow. It targets medical students, residents, and early-career physicians who want structured DDx practice and evidence-linked care plans without switching between multiple tools.

The free tier makes it accessible for learners. The Pro tier ($20 to $200 per month, pricing varies by role and institution) adds the ambient scribe and deeper literature integration. The tool has near-zero peer-reviewed validation and minimal clinician discussion in public forums, which limits its evidence base for purchase decisions in risk-averse health systems.

Glass Health fits solo clinicians and training programs willing to adopt early-stage tools with unproven ROI. Health systems requiring published effectiveness data or extensive EHR interoperability should wait for more mature offerings.

Why we picked it

Glass Health earned a silo pick in the AI Clinical Decision Support category because it integrates three workflows that typically require separate tools: differential diagnosis generation, evidence-linked assessment and plan drafting, and ambient SOAP note creation. Most competitors handle one of these well but force context-switching for the others.

The free Lite tier removes the adoption barrier for medical students and residents, a population underserved by expensive legacy DDx tools. This makes Glass Health a practical choice for individual learners who want to build diagnostic reasoning skills outside of paid institutional subscriptions.

The literature grounding distinguishes it from LLM-only assistants that hallucinate references. Glass surfaces PubMed citations and clinical guidelines inline with its recommendations, a feature that aligns with evidence-based practice expectations among attending physicians and residency program directors.

The ambient scribe integration in Pro tiers consolidates documentation workflows. Clinicians can dictate a patient encounter, receive a structured DDx, and export a draft SOAP note without toggling between Glass, UpToDate, and a separate scribe tool. This workflow compression is the core value proposition for practicing physicians.

What it does well

The differential diagnosis engine accepts free-text case presentations and returns ranked DDx lists with likelihood rationales. It mimics the clinical reasoning structure taught in medical school (chief complaint, HPI, PMH, exam findings, then DDx), which makes it intuitive for trainees. The tool highlights which findings support or refute each diagnosis, a teaching feature absent from simpler symptom-checkers.

Literature integration pulls from PubMed and major clinical guidelines (IDSA, AHA, USPSTF) to support assessment and plan recommendations. When the tool suggests a workup step or treatment, it cites the source guideline or study inline. This citation layer reduces the risk of acting on unsourced LLM output, a concern for any AI-assisted clinical tool.

The ambient scribe feature (Pro tier) listens to patient encounters and auto-generates SOAP notes with DDx and A&P sections pre-populated. Early adopters report time savings on documentation, though the tool does not integrate bidirectionally with EHRs, so clinicians still copy-paste into their charting system.

The free tier is unusually generous for a clinical AI tool. Medical students can run unlimited DDx cases without payment, making Glass Health a viable supplement to Isabel or other institutional DDx platforms that require school-wide licenses.

Where it falls short

Glass Health lacks FDA clearance as a clinical decision support tool and does not claim to meet FDA criteria for AI-enabled diagnostic devices. This regulatory gap limits adoption in health systems that require cleared or approved software for clinical workflows. The vendor has not published a roadmap toward FDA submission.

EHR integration is read-only at best and nonexistent in most deployments. The tool does not write back to Epic, Cerner, or Athenahealth. Clinicians must manually transfer DDx findings and draft notes into their EHR, which adds friction and raises copy-paste error risks. Competing tools like Nuance DAX integrate bidirectionally with major EHRs.

Peer-reviewed validation is absent. A PubMed search returns zero indexed studies evaluating Glass Health's diagnostic accuracy, time-to-documentation impact, or patient outcome effects. This evidence gap makes it difficult to justify ROI to hospital CFOs or to meet evidence standards for clinical pathway integration.

The pricing structure lacks transparency. The vendor advertises a range of $20 to $200 per month for Pro tiers but does not publish a clear pricing calculator or per-seat cost for group practices. Prospective buyers report needing to contact sales for quotes, which slows procurement and suggests negotiable pricing that disadvantages smaller practices.

Deployment realities

Glass Health runs as a standalone web app with no desktop client or mobile app. Clinicians access it via browser, which simplifies onboarding but prevents deep OS-level integration (no Siri dictation hooks, no iOS Health Records tie-ins). Training time is minimal for tech-comfortable clinicians: most users report productive use within 30 minutes of first login.

The ambient scribe requires microphone access and a quiet environment. It does not filter background noise as aggressively as Nuance or Suki, so ED and urgent care settings report lower transcription accuracy. The vendor recommends exam rooms with closed doors, which limits utility in open clinic layouts.

IT departments face minimal setup burden because the tool is SaaS-only with no on-prem deployment option. HIPAA compliance is vendor-managed, and Glass Health publishes a BAA. However, health systems that require on-prem AI for patient data sovereignty (common in academic medical centers with IRB-governed research) cannot deploy Glass Health without sending PHI to third-party servers.

Pricing realities

The free Lite tier includes unlimited DDx case runs, which makes it viable for medical students and residents on zero budget. The Lite tier omits the ambient scribe and limits literature citations to two per case, enough for learning but insufficient for documentation workflows.

Pro tier pricing ranges from $20 to $200 per month per clinician depending on specialty, practice size, and negotiated contract terms. The vendor does not publish a self-service pricing page, which suggests enterprise pricing variability. Solo family medicine physicians report $20 per month offers; specialists in larger groups report quotes near $100 per month. The $200 ceiling appears reserved for institutional deals with training programs.

Hidden costs include the labor cost of manual EHR data entry. Because Glass Health does not write to EHRs, clinicians must copy-paste notes, which takes 1 to 3 minutes per encounter. At 20 patients per day, this adds 30 to 60 minutes of clerical work daily, eroding the time savings from ambient documentation. Competing scribes like DAX integrate directly and eliminate this step.

Compliance + integration depth

Glass Health is HIPAA-compliant and offers a Business Associate Agreement for covered entities. The vendor has not published SOC 2 Type II or HITRUST certification status, which some health systems require for third-party software handling PHI. Prospective buyers should request attestation letters during procurement.

EHR integration is limited to manual copy-paste. The tool does not connect to Epic, Cerner, Athenahealth, or other major platforms via HL7, FHIR, or proprietary APIs. This means patient data must be typed into Glass Health manually, and generated notes must be copied back into the EHR. The lack of bidirectional integration is the most common dealbreaker cited by CMIOs evaluating the tool.

The tool has no published endorsements from specialty societies (AAFP, ACP, ACEP). It has not been evaluated by ECRI or Hayes for safety or effectiveness. The absence of third-party validation limits its credibility in evidence-based purchasing processes.

Vendor stability + roadmap

Glass Health was founded in 2021 and is headquartered in the United States. Public funding data is sparse; the company has not announced major venture rounds or acquisition by a larger health IT vendor. The small team size and limited public presence suggest early-stage venture backing rather than growth-stage capital.

The vendor's roadmap, based on product updates published on its website, emphasizes ambient scribe accuracy improvements and expanded guideline coverage. There is no public commitment to FDA clearance pursuit or EHR integration partnerships, both of which would accelerate enterprise adoption.

Customer references are thin. The vendor does not publish case studies or named health system deployments. The lack of referenceable customers makes due diligence harder for procurement teams and raises questions about production-scale use outside of individual clinician subscriptions.

How it compares

UpToDate remains the gold standard for evidence-based clinical information but requires manual DDx reasoning and does not generate documentation. Glass Health automates the DDx step and drafts the note, which saves time for clinicians who already subscribe to UpToDate for deep evidence review. The two tools complement rather than replace each other.

Isabel is a mature DDx engine with FDA clearance and published validation studies. It integrates with Epic and Cerner via third-party middleware. Isabel wins for health systems requiring regulatory clearance and EHR integration. Glass Health wins for solo clinicians prioritizing cost (Isabel requires institutional contracts) and for learners who value the ambient scribe feature Isabel lacks.

Nuance DAX and Suki are ambient scribes with deep EHR integrations and FDA clearance. They write directly to Epic and Cerner, eliminating copy-paste friction. DAX and Suki do not generate DDx lists or pull literature citations, so they serve documentation workflows but not clinical reasoning. Glass Health wins for clinicians who want both DDx and scribe in one tool. DAX wins for practices prioritizing seamless EHR write-back.

DXplain is a legacy DDx tool from Massachusetts General Hospital with strong academic validation. It lacks ambient scribe features and has a dated interface. Glass Health wins on usability and workflow integration. DXplain wins on peer-reviewed evidence and institutional trust for academic medical centers.

What clinicians say

Public clinician discussion of Glass Health is minimal. A search of Reddit medical communities (r/medicine, r/Residency, r/medicalschool) returned one mention in the past year, and it was a general question about guideline summaries rather than a direct review of Glass Health. The absence of organic user discussion suggests limited adoption or that early users are not yet vocal advocates.

The vendor's website includes unlabeled testimonials, but without named clinicians or institutional affiliations, these carry limited weight for evidence-based purchasing. Prospective buyers should request verifiable customer references during the sales process.

The lack of clinician-generated reviews on Doximity, Sermo, or medical Reddit suggests Glass Health has not reached critical mass among practicing physicians. This is common for tools in their first three years post-launch but makes peer validation difficult for risk-averse adopters.

What the literature says

Glass Health has zero peer-reviewed publications indexed in PubMed as of May 2026. There are no published studies evaluating its diagnostic accuracy, impact on documentation time, or effects on patient outcomes. This evidence gap is the single largest barrier to adoption in academic medical centers and health systems with evidence-based purchasing standards.

The absence of validation studies does not mean the tool is ineffective, but it does mean buyers must rely on vendor claims and anecdotal feedback rather than published data. Competing tools like Isabel and DXplain have multiple peer-reviewed studies demonstrating diagnostic sensitivity and specificity, which gives them a credibility advantage in procurement processes.

The vendor has not published white papers, case studies, or preprints describing the tool's underlying AI models, training data sources, or performance benchmarks. This opacity limits technical due diligence for IT and clinical informatics teams evaluating the tool.

Who it's for

Glass Health fits medical students and residents who want structured DDx practice outside of institutional tools. The free tier removes cost barriers, and the clinical reasoning workflow mirrors academic training. Program directors looking for supplemental teaching tools should consider Glass Health for case-based learning exercises.

Solo family medicine and internal medicine physicians in small practices who want an affordable ambient scribe with DDx support will find value in the $20 to $50 per month Pro tier. These clinicians typically lack institutional IT support for complex EHR integrations, so the standalone web app model is a feature rather than a limitation.

Health systems, IDNs, and large group practices requiring FDA-cleared tools, published effectiveness data, or bidirectional EHR integration should skip Glass Health until the vendor addresses these gaps. CMIOs evaluating clinical AI portfolios will find better-evidenced alternatives in Isabel (for DDx) and Nuance DAX (for ambient scribe).

The verdict

Glass Health is a capable early-stage clinical reasoning assistant with a workflow advantage (DDx plus scribe in one tool) and a pricing advantage (free tier for learners). It lacks the regulatory clearances, peer-reviewed validation, and EHR integration depth required for enterprise health system adoption. The evidence base is thin: zero PubMed studies and minimal clinician discussion in public forums.

If you are a medical student, resident, or early-career clinician looking for DDx practice and affordable ambient documentation, Glass Health is worth a trial. Start with the free tier to evaluate fit. If you are a solo or small-group clinician comfortable with early-stage tools and manual EHR workflows, the Pro tier at $20 to $50 per month offers reasonable value if the ambient scribe saves you 30 minutes per day.

If you are a CMIO, clinical informatics leader, or procurement officer at a health system requiring FDA clearance, published effectiveness studies, or seamless EHR integration, wait. Glass Health is not ready for enterprise deployment. Evaluate Isabel for DDx workflows and Nuance DAX or Suki for ambient scribes instead. Revisit Glass Health in 12 to 24 months if the vendor publishes validation data and announces EHR partnerships.